Authorized purpose: Passive worklist triage for suspected pleural effusion and/or pneumothorax in adult chest radiographs
Clinical role
Passive notification and prioritization in parallel with standard of care; it does not send a proactive alert, direct attention to image regions, alter the queue, or replace clinical review
Images and patients
X-ray/Radiography · Chest/lung, targeting pleural effusion and pneumothorax
Key limitation
Keep in mind: Not for standalone clinical decision-making; not a proactive alert; not intended to direct attention to specific image portions or findings other than pleural effusion/pneumothorax; technologist notification is contextual and not for clinical prioritization or action
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Passive worklist triage for suspected pleural effusion and/or pneumothorax in adult chest radiographs
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/lung, targeting pleural effusion and pneumothorax Input: Adult (>=18 years) AP and PA chest X-ray images in DICOM format, received as attached DICOM images or DICOM UIDs referencing stored images
Who uses it?Intended users: Appropriately trained medical specialists qualified to interpret chest radiographs, such as radiologists or other appropriately trained clinicians
What does the software produce?Output: Case-level flag or blank label for suspected pleural effusion and/or pneumothorax, shown in the PACS/workstation worklist; a newly generated DICOM or JSON result may be stored, with no markup on the original image. The packet also describes a contextual technologist notification within 15 minutes after interpretation
What is its most important limitation?Key limitation: Not for standalone clinical decision-making; not a proactive alert; not intended to direct attention to specific image portions or findings other than pleural effusion/pneumothorax; technologist notification is contextual and not for clinical prioritization or action
Clinical takeaway. Clinical role: Passive worklist triage for suspected pleural effusion and/or pneumothorax in adult chest radiographs
Evidence takeaway. Evidence from the reviewed source record: Internal independent testing used 1,209 pleural-effusion cases and 1,387 pneumothorax cases from 14 acute NHS sites, with three board-certified radiologist ground truths: sensitivity/specificity 82%/95% for pleural effusion and 89%/97% for pneumothorax. External validation used MIMIC-CXR, NIH-CXR, and CheXpert cohorts: pleural effusion n=2,509 with 867 positives, ROC AUC 0.988, sensitivity 92.62%, specificity 98.11%; pneumothorax n=3,245 with 2,114 positives, ROC AUC 0.972, sensitivity 93.38%, specificity 97.27%. Simultaneous prediction time was 4.8-10.4 seconds (95% CI 4.2-10.41 seconds)
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Passive worklist triage for suspected pleural effusion and/or pneumothorax in adult chest radiographs
Passive notification and prioritization in parallel with standard of care; it does not send a proactive alert, direct attention to image regions, alter the queue, or replace clinical review
Case-level flag or blank label for suspected pleural effusion and/or pneumothorax, shown in the PACS/workstation worklist; a newly generated DICOM or JSON result may be stored, with no markup on the original image. The packet also describes a contextual technologist notification within 15 minutes after interpretation
Not for standalone clinical decision-making; not a proactive alert; not intended to direct attention to specific image portions or findings other than pleural effusion/pneumothorax; technologist notification is contextual and not for clinical prioritization or action
Internal independent testing used 1,209 pleural-effusion cases and 1,387 pneumothorax cases from 14 acute NHS sites, with three board-certified radiologist ground truths: sensitivity/specificity 82%/95% for pleural effusion and 89%/97% for pneumothorax. External validation used MIMIC-CXR, NIH-CXR, and CheXpert cohorts: pleural effusion n=2,509 with 867 positives, ROC AUC 0.988, sensitivity 92.62%, specificity 98.11%; pneumothorax n=3,245 with 2,114 positives, ROC AUC 0.972, sensitivity 93.38%, specificity 97.27%. Simultaneous prediction time was 4.8-10.4 seconds (95% CI 4.2-10.41 seconds)
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Internal independent testing used 1,209 pleural-effusion cases and 1,387 pneumothorax cases from 14 acute NHS sites, with three board-certified radiologist ground truths: sensitivity/specificity 82%/95% for pleural effusion and 89%/97% for pneumothorax. External validation used MIMIC-CXR, NIH-CXR, and CheXpert cohorts: pleural effusion n=2,509 with 867 positives, ROC AUC 0.988, sensitivity 92.62%, specificity 98.11%; pneumothorax n=3,245 with 2,114 positives, ROC AUC 0.972, sensitivity 93.38%, specificity 97.27%. Simultaneous prediction time was 4.8-10.4 seconds (95% CI 4.2-10.41 seconds)
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
BraveCX regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K223754
Samplen=2981
IndependenceIndependence not established
K223754
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K223754. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Adult (>=18 years) AP and PA chest X-ray images in DICOM format, received as attached DICOM images or DICOM UIDs referencing stored images
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Licensed API described as deployable cloud-based, on premises, or integrated with third-party systems; supports DICOM storage including PACS or other local storage, produces DICOM/JSON results, and displays worklist flags
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes BraveCX as a licensed Application Programming Interface that can be deployed as a cloud-based service, directly on premises, or integrated with third-party systems. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "BraveCX is supplied as a licensed Application Programming Interface (API) that can be deployed either as a cloud-based service, directly on premises, or integrated with third-party systems.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Case-level flag or blank label for suspected pleural effusion and/or pneumothorax, shown in the PACS/workstation worklist; a newly generated DICOM or JSON result may be stored, with no markup on the original image. The packet also describes a contextual technologist notification within 15 minutes after interpretation
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Case-level flag or blank label for suspected pleural effusion and/or pneumothorax, shown in the PACS/workstation worklist; a newly generated DICOM or JSON result may be stored, with no markup on the original image. The packet also describes a contextual technologist notification within 15 minutes after interpretation
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes BraveCX as a licensed Application Programming Interface that can be deployed as a cloud-based service, directly on premises, or integrated with third-party systems. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "BraveCX is supplied as a licensed Application Programming Interface (API) that can be deployed either as a cloud-based service, directly on premises, or integrated with third-party systems.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Licensed API described as deployable cloud-based, on premises, or integrated with third-party systems; supports DICOM storage including PACS or other local storage, produces DICOM/JSON results, and displays worklist flags
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
9Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K223754 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.
Authorized purpose: Passive triage of adult AP chest radiographs for an endotracheal-tube tip more than 7 cm above the carina, less than 3 cm above the carina, below the carina in the right or left mainstem, or other listed malposition states.
Authorized purpose: Passive worklist prioritization for suspected pleural effusion and/or pneumothorax on frontal PA or AP chest radiographs in transitional adolescents aged 18-21 and adults aged 22 years and older; not diagnostic or a rule-out function.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.